This event has now taken place: you can read our report of it here and it is available to watch at https://bit.ly/resourcingforhealth.
On Thursday 28 January at 2:30pm GMT, the UK Working Group on NCDs will be cohosting a webinar on one of the hottest topics in global health: how to maximise available resources for global health in an era of Covid-19.
This 90-minute event will begin by setting out the options available to governments in low- and middle-income countries to raise revenue for health (raising, pooling and optimising domestic resources for health), and case studies will be provided on integration and efficiencies across disease areas, including NCDs and mental health. The discussion will then turn to an introduction to the new funding structure for COVID-19 – the Access to COVID-19 Tools Accelerator (ACT-A) – and how this funding could be used to help to reinforce health systems, support advances in universal health coverage and promote primary care services, rather than creating parallel COVID-specific systems. It is an opportunity to identify ways in which civil society can support better value for money from the ACT-A resources in different contexts.
The event is cohosted by Action for Global Health and The George Institute for Global Health. Confirmed speakers include Robert Yates (Chatham House), Javier Hourcade Bellocq (ACT-A Health Systems Connector representative), James Sale (United for Global Health), Jonathan Cushing (Transparency International) and Jane Hirst (The George Institute). The webinar will be chaired by Allison Beattie (formerly DFID, now an independent consultant).
The conversation on social media will use the hashtag #ResourcingForHealth. Please join us for the event and on social media.
The UKWG is very grateful to the cohosts of this event. The webinar was developed with the support of the NCD Alliance Civil Society Solidarity Fund on NCDs and COVID-19 (made possible thanks to the generous financial contributions of The Leona M. and Harry B. Helmsley Charitable Trust, Access Accelerated, Takeda, AstraZeneca and Upjohn (Pfizer)).
UK Working Group on NCDs 